Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$69.00 USD

69.00
3,405,133

-0.70 (-1.00%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Cigna (CI) Unit Ties Up to Offer Digital Health Tool to Clients

by Zacks Equity Research

Cigna's (CI) division, Cigna Healthcare, teams up with Virgin Pulse to make an effective digital health solution available to its clients, who can now improve their well-being.

Syneos Health (SYNH) to Go Private, Reports Q2 Performance

by Zacks Equity Research

Syneos Health (SYNH) announces shareholders' approval for the impending merger and releases second-quarter 2023 financial results.

Medtronic (MDT) Rides on Strong Global Growth, New Launches

by Zacks Equity Research

Medtronic (MDT) is gaining from positive sales momentum with the rollout of its differentiated Hugo robotic system in many international markets.

Accuray (ARAY) Q4 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Accuray (ARAY) reports a solid fiscal fourth quarter top line on the back of robust segmental performances.

Avanos (AVNS) Q2 Earnings and Revenues Fall Shy of Estimates

by Zacks Equity Research

Despite strength in Avanos' (AVNS) Digestive Health segment, its overall second-quarter results reflect soft performances.

Here's Why You Should Retain National Vision (EYE) Stock Now

by Zacks Equity Research

Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and technological investments.

QuidelOrtho (QDEL) Q2 Earnings Top Estimates, FY23 View Revised

by Zacks Equity Research

Despite solid performances by the Labs segment and Other region, QuidelOrtho (QDEL) reports soft overall top-line results in second-quarter 2023.

Masimo (MASI) Q2 Earnings Lag Estimates, Margins Rise

by Zacks Equity Research

Despite strength in Hearables category, Masimo's (MASI) overall second-quarter results reflect soft performances.

PacBio (PACB) Inks Research Collaboration for Genome Sequencing

by Zacks Equity Research

PacBio (PACB) and GeneDx sign a deal with the University of Washington to study long-read sequencing in rare diseases. The study will use PacBio's Revio system to explore novel variants.

Inogen (INGN) Q2 Earnings Beat Estimates, Revenues Down Y/Y

by Zacks Equity Research

Despite higher domestic business-to-business sales and rental revenues, Inogen's (INGN) overall second-quarter results reflect soft performances.

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Insulet (PODD) on the strength of the Omnipod 5 AID system.

OPKO Health (OPK) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall second-quarter results reflect soft performances.

Sanghamitra Saha headshot

5 Top Stocks Likely to Beat Earnings Estimates

by Sanghamitra Saha

These top-ranked stocks are likely to beat on the bottom line in their upcoming releases. Tap Coty (COTY), BJ's Restaurants (BJRI), DexCom (DXCM), Livent (LTHM) and D.R. Horton (DHI).

DexCom (DXCM) Q2 Earnings Beat Estimates, Volumes Remain Strong

by Zacks Equity Research

DexCom's (DXCM) second-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

Compared to Estimates, DexCom (DXCM) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

DexCom (DXCM) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

DexCom (DXCM) delivered earnings and revenue surprises of 54.55% and 4.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Toyota, Deere, Starbucks, AbbVie and DexCom

by Zacks Equity Research

Toyota, Deere, Starbucks, AbbVie and DexCom are included in this Analyst Blog.

Sheraz Mian headshot

Q2 Earnings Season Scorecard and Analyst Reports for Toyota, Deere & Starbucks

by Sheraz Mian

Today's Research Daily features a real-time update on the Q2 earnings season, in addition to featuring updated reports on Toyota Motor(TM), Deere & Company (DE) and Starbucks (SBUX).

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Are Medical Stocks Lagging Boston Scientific (BSX) This Year?

by Zacks Equity Research

Here is how Boston Scientific (BSX) and DexCom (DXCM) have performed compared to their sector so far this year.

DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) second-quarter 2023 results are likely to reflect rising volumes across all channels.

DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

DexCom (DXCM) closed the most recent trading day at $130.60, moving -0.04% from the previous trading session.

Benjamin Rains headshot

3 Highly-Ranked Large Cap Stocks to Buy Before Earnings for Big Upside

by Benjamin Rains

Exploring three highly-ranked large-cap stocks--Honeywell, DexCom, and NextEra Energy--that investors might want to buy before their upcoming earnings releases for both near-term and long-term upside.

Select Medical (SEM) Expects Q2 Adjusted EBITDA to Jump 21% Y/Y

by Zacks Equity Research

Select Medical's (SEM) strong second-quarter 2023 guidance highlights improving performance in all four segments.

NextGen (NXGN) Settles Misrepresentation Allegations for $31M

by Zacks Equity Research

NextGen (NXGN) settles accusations of software fraud and anti-kickback violations for $31M. However, the company denies any wrongdoing.